EUROPEAN MEDICINES AGENCY DECISION

of 28 August 2009


(ONLY THE ENGLISH TEXT IS AUTHENTIC)
EUROPEAN MEDICINES AGENCY DECISION

of 28 August 2009


THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,


Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Merck Sharp & Dohme (Europe), Inc. on 27 February 2009 under Article 13 of Regulation (EC) No 1901/2006 as amended,

Having regard to the Opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 May 2009, and its Correction issued on 28 August 2009 in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

(1) The Paediatric Committee has given an opinion on the granting of a product specific waiver,

(2) It is therefore appropriate to adopt a Decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1
² OJ L 136, 30.4.2004, p. 1
HAS ADOPTED THIS DECISION:

Article 1

A waiver for sitagliptin phosphate monohydrate / simvastatin, film-coated tablet, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision, which supersedes the previous decision of the European Medicines Agency P/142/2009 of 15 July 2009 on identical matter, is addressed to Merck Sharp & Dohme (Europe), Inc., 5 Clos du Lynx, 1200 Brussels, Belgium.

Done at London, 28 August 2009

For the European Medicines Agency
Thomas Löngren
Executive Director

(Signature on file)
OPINION OF THE PAEDIATRIC COMMITTEE ON THE GRANTING OF A PRODUCT-SPECIFIC WAIVER

Scope of the application

Active substance(s):
Sitagliptin phosphate monohydrate / simvastatin

Condition(s):
Type 2 diabetes mellitus and hypercholesterolaemia

Pharmaceutical form(s):
Film-coated tablet

Route(s) of administration:
Oral use

Name/corporate name of the waiver applicant:
Merck Sharp & Dohme (Europe), Inc.

Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme (Europe), Inc. submitted to the EMEA on 27 February 2009 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 02 April 2009.
**Opinion**

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report, to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee member agree with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annex.

London, 29 May 2009

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)
ANNEX I

GROUNDS FOR THE GRANTING OF THE WAIVER
GROUNDS FOR THE GRANTING OF THE WAIVER

- **Condition**

  Type 2 diabetes mellitus and hypercholesterolaemia

  The waiver applies to:

  All subsets of the paediatric population from birth to less than 18 years of age,

  for sitagliptin phosphate monohydrate / simvastatin, film-coated tablet, oral use,

  on the grounds that clinical studies cannot fulfil a therapeutic need of the paediatric population.